APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pulmonary Arterial Hypertension Treatment Industry Research Report 2026

20 December 2025111 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Pulmonary Arterial Hypertension Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pulmonary Arterial Hypertension Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pulmonary Arterial Hypertension Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pulmonary Arterial Hypertension Treatment include GSK, Teva Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Bayer AG, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc and Actelion Inc. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Pulmonary Arterial Hypertension Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pulmonary Arterial Hypertension Treatment.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Arterial Hypertension Treatment Market by Company

GSK

Teva Pharmaceuticals Inc

Eli Lilly and Company

Pfizer Inc

Bayer AG

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Actelion Inc

Pulmonary Arterial Hypertension Treatment Segment by Type

Vasodilators

Endothelin Receptor Antagonists (ERA)

Phosphodiesterase 5 (PDE 5) Inhibitors

Soluble Guanylate Cyclase (SGC) Stimulator

Pulmonary Arterial Hypertension Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Pulmonary Arterial Hypertension Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Pulmonary Arterial Hypertension Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2021-2026) Table 7. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2027-2032) Table 9. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2021-2026) Table 11. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2027-2032) Table 13. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2021-2026) Table 16. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2027-2032) Table 18. Pulmonary Arterial Hypertension Treatment Industry Trends Table 19. Pulmonary Arterial Hypertension Treatment Industry Drivers Table 20. Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges Table 21. Pulmonary Arterial Hypertension Treatment Market Restraints Table 22. Global Top Pulmonary Arterial Hypertension Treatment Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2021-2026) Table 24. Global Pulmonary Arterial Hypertension Treatment Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Pulmonary Arterial Hypertension Treatment, Headquarters and Area Served Table 26. Global Pulmonary Arterial Hypertension Treatment Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Pulmonary Arterial Hypertension Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032) & (US$ Million) Table 45. GSK Company Information Table 46. GSK Business Overview Table 47. GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 48. GSK Pulmonary Arterial Hypertension Treatment Product Portfolio Table 49. GSK Recent Developments Table 50. Teva Pharmaceuticals Inc Company Information Table 51. Teva Pharmaceuticals Inc Business Overview Table 52. Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 53. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 54. Teva Pharmaceuticals Inc Recent Developments Table 55. Eli Lilly and Company Company Information Table 56. Eli Lilly and Company Business Overview Table 57. Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 58. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio Table 59. Eli Lilly and Company Recent Developments Table 60. Pfizer Inc Company Information Table 61. Pfizer Inc Business Overview Table 62. Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 63. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 64. Pfizer Inc Recent Developments Table 65. Bayer AG Company Information Table 66. Bayer AG Business Overview Table 67. Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 68. Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio Table 69. Bayer AG Recent Developments Table 70. United Therapeutic Corporation Company Information Table 71. United Therapeutic Corporation Business Overview Table 72. United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 73. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio Table 74. United Therapeutic Corporation Recent Developments Table 75. SteadyMed Ltd Company Information Table 76. SteadyMed Ltd Business Overview Table 77. SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 78. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio Table 79. SteadyMed Ltd Recent Developments Table 80. Gilead Sciences, Inc Company Information Table 81. Gilead Sciences, Inc Business Overview Table 82. Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 83. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 84. Gilead Sciences, Inc Recent Developments Table 85. Actelion Inc Company Information Table 86. Actelion Inc Business Overview Table 87. Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026) & (US$ Million) Table 88. Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 89. Actelion Inc Recent Developments Table 90. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pulmonary Arterial Hypertension Treatment Product Image Figure 5. Global Pulmonary Arterial Hypertension Treatment Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Pulmonary Arterial Hypertension Treatment Market Share by Type: 2025 VS 2032 Figure 7. Vasodilators Product Figure 8. Endothelin Receptor Antagonists (ERA) Product Figure 9. Phosphodiesterase 5 (PDE 5) Inhibitors Product Figure 10. Soluble Guanylate Cyclase (SGC) Stimulator Product Figure 11. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pulmonary Arterial Hypertension Treatment Market Share by Application: 2025 VS 2032 Figure 13. Hospital Pharmacies Product Figure 14. Online Pharmacies Product Figure 15. Retail Pharmacies Product Figure 16. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 17. Global Pulmonary Arterial Hypertension Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Pulmonary Arterial Hypertension Treatment Market Share by Region: 2025 VS 2032 Figure 19. Global Pulmonary Arterial Hypertension Treatment Market Share by Players in 2025 Figure 20. Global Pulmonary Arterial Hypertension Treatment Manufacturers Established Date Figure 21. Global Top 5 and 10 Pulmonary Arterial Hypertension Treatment Players Market Share by Revenue in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. North America Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 25. United States Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Canada Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Mexico Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 28. Europe Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 30. Germany Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. France Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. U.K. Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Italy Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Spain Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Russia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Netherlands Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Nordic Countries Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 40. China Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Japan Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. South Korea Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 45. Australia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. China Taiwan Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. Southeast Asia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 50. Brazil Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Argentina Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Chile Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Colombia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Peru Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. GSK Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 56. Teva Pharmaceuticals Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 57. Eli Lilly and Company Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 58. Pfizer Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 59. Bayer AG Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 60. United Therapeutic Corporation Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 61. SteadyMed Ltd Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 62. Gilead Sciences, Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026) Figure 63. Actelion Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2021-2026)

Scope & coverage.

Types
  • Vasodilators
  • Endothelin Receptor Antagonists (ERA)
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulator
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Teva Pharmaceuticals Inc
  • Eli Lilly and Company
  • Pfizer Inc
  • Bayer AG
  • United Therapeutic Corporation
  • SteadyMed Ltd
  • Gilead Sciences, Inc
  • Actelion Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Pulmonary Arterial Hypertension Treatment by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Vasodilators
  5. 2.2.3 Endothelin Receptor Antagonists (ERA)
  6. 2.2.4 Phosphodiesterase 5 (PDE 5) Inhibitors
  7. 2.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
  8. 2.3 Pulmonary Arterial Hypertension Treatment by Application
  9. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  10. 2.3.2 Hospital Pharmacies
  11. 2.3.3 Online Pharmacies
  12. 2.3.4 Retail Pharmacies
  13. 2.4 Assumptions and Limitations
3 Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
  1. 3.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Type (2021-2026)
  2. 3.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2027-2032)
4 Pulmonary Arterial Hypertension Treatment Breakdown Data by Application
  1. 4.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Application (2021-2026)
  2. 4.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Pulmonary Arterial Hypertension Treatment Market Perspective (2021-2032)
  2. 5.2 Global Pulmonary Arterial Hypertension Treatment Growth Trends by Region
  3. 5.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Pulmonary Arterial Hypertension Treatment Historic Market Size by Region (2021-2026)
  5. 5.2.3 Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Region (2027-2032)
  6. 5.3 Pulmonary Arterial Hypertension Treatment Market Dynamics
  7. 5.3.1 Pulmonary Arterial Hypertension Treatment Industry Trends
  8. 5.3.2 Pulmonary Arterial Hypertension Treatment Market Drivers
  9. 5.3.3 Pulmonary Arterial Hypertension Treatment Market Challenges
  10. 5.3.4 Pulmonary Arterial Hypertension Treatment Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Pulmonary Arterial Hypertension Treatment Players by Revenue
  2. 6.1.1 Global Top Pulmonary Arterial Hypertension Treatment Players by Revenue (2021-2026)
  3. 6.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Pulmonary Arterial Hypertension Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Pulmonary Arterial Hypertension Treatment Head Office and Area Served
  6. 6.4 Global Pulmonary Arterial Hypertension Treatment Players, Product Type & Application
  7. 6.5 Global Pulmonary Arterial Hypertension Treatment Manufacturers Established Date
  8. 6.6 Global Pulmonary Arterial Hypertension Treatment Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  2. 7.2 North America Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  4. 7.4 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  2. 8.2 Europe Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  4. 8.4 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  2. 9.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  2. 10.2 South America Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  4. 10.4 South America Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  2. 11.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 GSK
  2. 12.1.1 GSK Company Information
  3. 12.1.2 GSK Business Overview
  4. 12.1.3 GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  5. 12.1.4 GSK Pulmonary Arterial Hypertension Treatment Product Portfolio
  6. 12.1.5 GSK Recent Developments
  7. 12.2 Teva Pharmaceuticals Inc
  8. 12.2.1 Teva Pharmaceuticals Inc Company Information
  9. 12.2.2 Teva Pharmaceuticals Inc Business Overview
  10. 12.2.3 Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  11. 12.2.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  12. 12.2.5 Teva Pharmaceuticals Inc Recent Developments
  13. 12.3 Eli Lilly and Company
  14. 12.3.1 Eli Lilly and Company Company Information
  15. 12.3.2 Eli Lilly and Company Business Overview
  16. 12.3.3 Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  17. 12.3.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio
  18. 12.3.5 Eli Lilly and Company Recent Developments
  19. 12.4 Pfizer Inc
  20. 12.4.1 Pfizer Inc Company Information
  21. 12.4.2 Pfizer Inc Business Overview
  22. 12.4.3 Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  23. 12.4.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  24. 12.4.5 Pfizer Inc Recent Developments
  25. 12.5 Bayer AG
  26. 12.5.1 Bayer AG Company Information
  27. 12.5.2 Bayer AG Business Overview
  28. 12.5.3 Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  29. 12.5.4 Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio
  30. 12.5.5 Bayer AG Recent Developments
  31. 12.6 United Therapeutic Corporation
  32. 12.6.1 United Therapeutic Corporation Company Information
  33. 12.6.2 United Therapeutic Corporation Business Overview
  34. 12.6.3 United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  35. 12.6.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio
  36. 12.6.5 United Therapeutic Corporation Recent Developments
  37. 12.7 SteadyMed Ltd
  38. 12.7.1 SteadyMed Ltd Company Information
  39. 12.7.2 SteadyMed Ltd Business Overview
  40. 12.7.3 SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  41. 12.7.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio
  42. 12.7.5 SteadyMed Ltd Recent Developments
  43. 12.8 Gilead Sciences, Inc
  44. 12.8.1 Gilead Sciences, Inc Company Information
  45. 12.8.2 Gilead Sciences, Inc Business Overview
  46. 12.8.3 Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  47. 12.8.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  48. 12.8.5 Gilead Sciences, Inc Recent Developments
  49. 12.9 Actelion Inc
  50. 12.9.1 Actelion Inc Company Information
  51. 12.9.2 Actelion Inc Business Overview
  52. 12.9.3 Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2021-2026)
  53. 12.9.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  54. 12.9.5 Actelion Inc Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst